Immuron Ltd has released a press release.
Immuron FY23 Sales increase 136% on FY22 Sales
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Immuron Initiates Recruitment of Travelan Clinical Study
- FDA Removed Clinical Hold on Campylobacter ETEC Therapeutic
- Q3 FY23 Business Update Presentation
- Immuron Q3 Sales reach 150% of 1H Sales
- Business Update Presentation
Later from Immuron
- Immuron enrols patients in Travelan clinical study
- Immuron Receives TGA GMP Clearance
- Immuron achieves record monthly Travelan sales
- Immuron achieves record quarterly Travelan sales
- First Patients Enrolled in Campylobacter Clinical Study
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron